Evaluation of the toxicity and quality of life in patients with colorectal cancer treated with chemotherapy;Avaliação da qualidade de vida e toxicidades em pacientes com câncer colorretal tratados com quimioterapia adjuvante baseada em fluoropirimidinas

Arquivos de Gastroenterologia

Volumn 43, Issue 2, 2006, Pages 94-101

  Roque, Vanessa Maria Nunes ^a   Forones, Nora Manoukian ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Chemotherapy, adjuvant; Colorectal neoplasms; Drug toxicity; Pyrimidines; Quality of life

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; MALE; NAUSEA; NEUTROPENIA; PALLIATIVE THERAPY; QUESTIONNAIRE; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA;

EID: 33748755350     PISSN: 00042803     EISSN: 16784219     Source Type: Journal    
DOI: 10.1590/s0004-28032006000200007     Document Type: Article

References (34)

1. nd ed. New York: Churchill Livingstone; c2000. p.1611-60.
2. Almeida EPM. Ocorrência e intensidade de náuseas, vômito e diarréia, em pacientes com neoplasia de cólon em quimioterapia ambulatorial - indicadores para avaliar resultados das orientações de enfermagem [tese]. São Paulo: Universidade Federal de São Paulo; 2000.
3. Alves LC. Correlação entre adaptação psicossocial à colostomia permanente e resposta psicológica ao câncer. Psiquiatria Prática Médica. 2000;33(4):1-7.
4. Andre T, Boni C, Mounedji-Boundiaf L. Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343-51.
5. Boery EN. Qualidade de vida de pacientes adultos com câncer de pulmão submetidos a quimioterapia ambulatorial [tese]. São Paulo: Universidade Federal de São Paulo; 2003.
6. Brennan J, Steele RJ. Prospective analysis of quality of life and survival following mesorectal excision for rectal cancer. Br J Surg. 2002;89:495.
7. Chiara S, Nobile MT, Vicenti M, Lionetto R, Gozza A, Barzacchi MC, Sanguineti O, Repetto L, Rosso R. Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother Pharmacol. 1998;42:336-40.
8. Fleck MPA, Louzada S, Xavier M, Chachamovich E, Vieira G, Santos L, Pinzon V. Aplicação da versão em português do instrumento abreviado de avaliação da Qualidade de vida "Whoqol bref". Rev Saúde Pública. 2000;34:178-83.
9. Gill TM, Feinstein AR. A critical appraisal of the quality of quality of life measurements. JAMA. 1994;272:619-26.
10. Gough IR. Quality of life as an outcome variable in oncology and surgery. Aust N Z J Surg. 1994;64:227-35.
11. Gouveia-Sobrinho EA, Carvalho MB, Franzi SA. Aspectos e tendências da avaliação da qualidade de vida de pacientes com câncer de cabeça e pescoço. Rev Soc Bras Cancerol. 2001;4(15):1-7.
12. Gramont A, Bosset JF, Milan C. Randomized trial comparing monthly low-dose leucovorin and fluourouracil bolus with bimonthly high-dose leucovorin and fluourouracil bolus plus continuos infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol. 1997;15:808-15.
13. Hospers G, Shaapveld M. Phase III study of bolus 5 fluorouracil (5FU) folinic acid vs high dose 24h 5 FU infusion/ folinic acid mais oxaliplatin (OXA) in metastatic colorectal cancer (MCRC) [abstract]. Proc Am Soc Clin Oncol. 2004;23:255.
14. Instituto Nacional do Câncer - INCA. Estimativa de incidência e mortalidade. [citado 2005 jul 10]. Disponível em: URL: http://www.inca.org.br/
15. Kumar SK, Goldberg RM. Adjuvant chemotherapy for colon cancer. Curr Oncol Rep. 2001;3:94-101.
16. Levin RD, Gupta D, Hoffman S, Granick J, Neelam R, Vashi PG, Daehler M, Wodek T, Quinn K, Lis CG. Quality of life assessment in clinical oncology: implications for prognosis in advanced colorectal cancer [abstract]. Proc Am Soc Clin Oncol. 2004;23:294.
17. Lis CG, Gupta D, Levin RD, Granick J, Neelam R, Hoffman S, Vashi PG, Lammersfeld CA. Quality of life outcomes of advanced colorectal cancer in a integrative treatment setting: The Cancer Treatment Centers of America experience. Proc Am Soc Clin Oncol. 2004;23:293.
18. Maisey NR, Norman A, Watson M, Allen MJ, Hill ME, Cunningham D. Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur J Cancer. 2002;38:1351-7.
19. McDonough EM, Varvares MA, Dunphy FR, Dunleavy T, Dunphy CH, Boyd JH. Changes in quality-of-life results in a population of patients treated for squamous cell carcinoma of the head and neck. Head Neck. 1997;18:487-93.
20. Morton RP. Evolution of quality of life assessment in head and neck cancer. J Laringol Otol. 1995;109:1029-35.
21. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancer in 1985. Int J Cancer. 1993;,54:594-606.
22. Polyzos A, Tsavaris N, Giannopoulos A, Bacoyiannis C, Papadimas V, Kalahanis N, Karatzas G, Kosmas C, Sakelaropoulos N, Archimandritis A, Papachristodoulou A, Kosmidis P. Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial. Cancer Chemother Pharmacol. 1996;38:292-7.
23. Ramsey SD, Andersen MR, Etzioni R, Moinpour C, Peacock S, Potosky A, Urban N. Quality of life in survivors of colorectal carcinoma. Cancer. 2000;88:1294-303.
24. Salud A, Saigi E, Batiste-Alentorn E, Losa F, Cirera L, Mendez M, Campos JM, Galan A, Escudero MP, Nogue M. Randomized phase IV trial of oral tegafur and low dose leucovorin versus intravenous 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer (ACC): final results [abstract]. Proc Am Soc Clin Oncol. 2004;23:257.
25. Skeel RT, Ganz PA. Systematic assessment of the patient with cancer and long-term medical complications of treatment. In: Skeel RT, Lachant NA, editors. Handbook of cancer chemotherapy. 4th ed. Boston: Brown, Little; c1995. p.95-115.
26. Starlin N, Chau I, Norman AR, Tait D, Iveson T, Hill M, Hickish T, Lofts F, Jodrell D, Cunningham D. A randomized comparison between six months of bolus fluorouracil (5 FU) leucovorin (LV) and twelve weeks of protracted venous infusion (PVI) 5 FU as adjuvant treatment in colorectal cancer: an update with 5 years follow-up [abstract]. Proc Am Soc Clin Oncol. 2004;23:251.
27. Stein BN, Petrelli NJ, Douglass HO. Age and sex are independent predictors of 5FU toxicity. Cancer. 1995;75:11-7.
28. Tomiak A, Vicent M, Kocha W, Taylor M, Winquist E, Keith B, Sawyer M, Griffeth S, Whiston F, Stitt L. Standard dose (Mayo Clinic) 5-fluorouracil and low dose folinic acid: prohibitive toxicity? Am J Clin Oncol. 2000;23:94-8.
29. Trentham-Dietz A, Remington PL, Moinpour CM, Hampton JM, Sapp AL, Newcomb PA. Health-related quality of life in female long-term colorectal cancer survivors. Oncologist. 2003;8:342-9.
30. Tsalic M, Bar-Sela G, Beny A, Visel B, Haim N. Severe toxicity related to the 5-fluorouracil/leucovorin combination (the Mayo Clinic regimen): a prospective study in colorectal cancer patients. Am J Clin Oncol. 2003;26:103-6.
31. Weinerman B. Increased incidence of toxicity in elderly females treated with 5FU, leucovorin [abstract]. Am Soc Clin Oncol. 1996;15:225.
32. WHOQOL Group. Versão em português dos instrumentos de avaliação de qualidade de vida (WHOQOL). Porto Alegre: FAMED - Universidade Federal do Rio Grande do Sul; 1998. Disponível em: URL: http://www.ufrgs.br/psiq.
33. Wolmark N, Rockette H, Fisher B. The benefit of leucovorin modulated fluorouracil as post-operative adjuvant therapy for primary colon cancer. Results from National Surgical Adjuvant Breast and Bowel Project protocol c-03. J Clin Oncol. 1993;11:1879-87.
34. Zalcberg J, Cunningham D, Rath U. Modulate 5FU: female gender and increasing age are associated with significantly more grade 3 or 4 leucopenia and mucositis [abstract]. Proc Am Soc Clin Oncol. 1996;15:201.